AT-Patch (ATP-C130/ATP-C70) vs Tempus ECG-AF
AI Verdict
Choose AT-Patch (ATP-C130/ATP-C70) if…
Choose AT-Patch if you require continuous, long-term cardiac monitoring for up to 14 days to detect intermittent arrhythmias, especially when patient comfort and mobility are crucial. This wearable device is ideal for patients needing extended monitoring outside of a clinical setting, offering a shower-proof design and integrated AI for comprehensive arrhythmia analysis.
View AT-Patch (ATP-C130/ATP-C70) →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your objective is to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within the next 12 months, utilizing existing 12-lead ECG data. This AI-powered software solution is best suited for integrating into cardiology workflows to enhance risk stratification and guide earlier follow-up for at-risk individuals.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AT-Patch (ATP-C130/ATP-C70) | Tempus ECG-AF |
|---|---|---|
| Pricing | N/a | Contact vendor |
| Deployment | Wearable device for patients; analysis software deployed on-premise at medical institutions. | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AT-Patch (ATP-C130/ATP-C70)AT-Patch (Tool A) offers superior patient usability with its compact, lightweight, and shower-proof wearable design, requiring no charging or electrode replacement during up to 14 days of continuous monitoring. The accompanying smartphone app (AT-Note) further enhances patient engagement by allowing live ECG viewing and symptom recording, making the monitoring experience less intrusive and more convenient for the patient.
Clinical Value
AT-Patch (ATP-C130/ATP-C70)AT-Patch (Tool A) provides comprehensive diagnostic clinical value through up to 14 days of continuous ECG monitoring, which is crucial for detecting intermittent arrhythmias often missed by shorter recordings. Its AI-powered analysis software (AT-Report) is designed for enhanced arrhythmia detection, offering a broader diagnostic scope for various cardiac conditions.
Pricing & Value
Tempus ECG-AFTempus ECG-AF (Tool B) demonstrates clearer financial value with explicit mention of CMS reimbursement availability (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). This transparency and established reimbursement pathway provide a significant advantage for healthcare institutions in assessing the economic viability of adopting the solution.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF (Tool B) exhibits stronger enterprise readiness by explicitly stating HIPAA compliance and the availability of a Business Associate Agreement (BAA). Its deployment as a software solution integrated into healthcare facility systems suggests easier implementation and less IT overhead compared to Tool A's on-premise software deployment.
Innovation
Tempus ECG-AFTempus ECG-AF (Tool B) represents a more innovative application of AI by leveraging existing 12-lead ECG data to predict the risk of developing atrial fibrillation within 12 months in a specific patient population. This predictive capability from a standard diagnostic test offers a novel approach to proactive and preventative cardiac care.
Support & Docs
Tempus ECG-AFTempus ECG-AF (Tool B) offers a more detailed and multi-channel support framework, including phone, email, and live chat options, with specified business hours and typical response times for inquiries. While AT-Patch (Tool A) provides user manuals and contact forms, Tempus's explicit support structure and dedicated cardiology support team suggest a more robust and transparent support system for enterprise clients.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AT-Patch (ATP-C130/ATP-C70) | Tempus ECG-AF |
|---|---|---|
| Name | AT-Patch (ATP-C130/ATP-C70) | Tempus ECG-AF |
| Company | ATsens Co. | Tempus AI, Inc. |
| Description | FDA-cleared wearable ECG monitor offering up to 14 days of continuous cardiac monitoring with high accuracy, a shower-proof design, and integrated AI-powered analysis software for enhanced arrhythmia detection. | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Categories | Cardiology AI, Wearables & Remote Monitoring (RPM) | Cardiology AI |
| Specialties | Cardiology, Family Medicine, Internal Medicine | Cardiology, Geriatrics, Internal Medicine |
| Key Features (Primary) | Up to 14 days of continuous ECG monitoring (ATP-C130) | AI-based algorithm for 12-lead ECG analysis |
Videos
Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring AT-Patch (ATP-C130/ATP-C70) or Tempus ECG-AF
Backers
Who funded each tool's parent company.